drugset / Trial / NCT06537843
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Phase 2
Recruiting
100 enrolled
Hospital Municipal São José
Hospital Amaral Carvalho. Jau, SP, Brazil · collabHospital Ophir Loyola. Belem, PA, Brazil · collabHospital Universitario Polydoro Ernani de São Thiago. Florianopolis, SC, Brazil · collabHospital de Clínicas da UFPR. Curitiba, PR, Brazil · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Subcutaneous |
| Subject | Metformin | Small molecule | 850 mg | Oral |
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |